Targovax logoTargovax logo

  • About
    About
    Close
      • About Targovax
      • Management Team
      • Board of Directors
      • Careers
        • Director/Manager, Clinical Development
        • Scientist
  • Technology
    Technology
    Close
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
  • Pipeline
    Pipeline
    Close
      • Our pipeline
      • Development Program
        • Melanoma
        • Mesothelioma
        • Next generation viruses
  • Partnering
  • Investors & Media
    Investors & Media
    Close
      • Our strategy
      • Press releases
      • Capital markets day 2021
      • Financial Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Events
      • Contact
      • Subscribe
  • Governance
    Governance
    Close
      • Corporate Governance Policy
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
  • Contacts
    Contacts
    Close
      • Offices
      • Investors & Media
    • About
      • About Targovax
      • Management Team
      • Board of Directors
      • Collaborations
      • Careers
        • Scientist
    • Technology
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
    • Pipeline
      • Our pipeline
      • Development program
    • Partnering
      • TG Mutant RAS neoantigen vaccine – Available for partnering
    • Investors & Media
      • Our strategy
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Financial Reports
      • Press releases
      • Presentations
      • Prospectus
      • Debt
      • Events
      • Subscribe
      • Contact
    • Governance
      • Corporate Governance Report
      • Corporate Social Responsibility Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
    • Contacts
      • Offices
      • Investors & Media

    Events
    Share price
    Share price
    Upcoming events
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • All years
    General Meetings
      • All events
      • Financial events
      • Other events
    IR contact
    Dr Lubor Gaal
    Dr Lubor Gaal
    Chief Financial Officer
    lubor.gaal@targovax.com
    (+34) 683 343 811
    Renate Birkeli
    Renate Birkeli
    Investor Relations
    renate.birkeli@targovax.com
    (+47) 922 61 624

    Q3 interim report 2022

    Targovax ASA (OSE: TRVX) announced its third quarter 2022 results on Thursday 3 November 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press. 

    • Report
    • Presentation
    • Webcast
    Read the report

    Subscribe

    Read more about our Protection of your personal data.
    • PRINT
    • STAY CONNECTED
    • Cookies
    • Privacy policy